Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the New Drug Application (NDA) for its
investigational fertility treatment, corifollitropin alfa, has been
accepted for standard review by the U.S. Food and Drug Administration
(FDA). Merck is seeking FDA approval of corifollitropin alfa for
Controlled Ovarian Stimulation (COS) in women participating in assisted
reproductive technology.
Language:
English
Contact:
MerckMedia:Pam Eisele, 908-423-5042orTina Grasso, 267-893-9783orInvestors:Carol Ferguson, 908-423-4465
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Food and Drug Administration (FDA) | Merck | New Drug Applications | Ovaries | Pharmaceuticals | Reproduction Medicine | Women